Compare
Silo Pharma, Inc. vs Inovio Pharmaceuticals, Inc. vs Connect Biopharma Holdings Ltd vs Avalo Therapeutics, Inc.
| Latest fiscal year | Silo Pharma, Inc. SILO | Inovio Pharmaceuticals, Inc. INO | Connect Biopharma Holdings Ltd CNTB | Avalo Therapeutics, Inc. AVTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $72.1K | $65.3K | $64.0K | $59.0K |
| Revenue growth (YoY) | 0.0% | -70.0% | -99.8% | -86.6% |
| Gross margin | 38.6% | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$4.23M | -$84.95M | -$55.48M | -$78.26M |
| EPS (Diluted) | -$0.50 | -$1.81 | -$1.00 | -$5.84 |
| Operating cash flow | -$4.66M | -$88.63M | -$51.21M | -$51.46M |
| Free cash flow | n/a | -$88.92M | -$51.64M | n/a |
| Cash & equivalents | $4.75M | $44.27M | $38.34M | $15.86M |
| Total assets | $7.61M | $74.31M | $56.08M | $116.46M |
| Total liabilities | $1.30M | $50.21M | $14.10M | $33.41M |
| Shareholders' equity | $6.31M | $24.10M | $41.98M | $83.05M |
| Return on year-end equity | -67.0% | -352.5% | -132.2% | -94.2% |
| Shares outstanding | 13.32M | 69.00M | 56.44M | 18.51M |
Revenue, most recent five fiscal years
| Fiscal year | Silo Pharma, Inc. | Inovio Pharmaceuticals, Inc. | Connect Biopharma Holdings Ltd | Avalo Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $72.1K Ended 2025-12-31 | $65.3K Ended 2025-12-31 | $64.0K Ended 2025-12-31 | $59.0K Ended 2025-12-31 |
| 1 year earlier | $72.1K Ended 2024-12-31 | $217.8K Ended 2024-12-31 | $26.03M Ended 2024-12-31 | $441.0K Ended 2024-12-31 |
| 2 years earlier | $72.1K Ended 2023-12-31 | $832.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $1.92M Ended 2023-12-31 |
| 3 years earlier | $72.1K Ended 2022-12-31 | $10.26M Ended 2022-12-31 | n/a | $18.05M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.77M Ended 2021-12-31 | n/a | $5.40M Ended 2021-12-31 |